Abstract
This prospective study was carried out on 53 in-patients suffering from chronic schizophrenia. Before the Risperidone treatment they were on the convenient antipsychotic therapy - haloperidol average doses 9.6 mg pro die, or Fluphenazine average 4.2 mg pro die.The aim of the study was to follow up therapeutically effects of Risperidone, using PANSS scale for schizophrenia, during two months, by two- weeks visits.ResultsOn average dose of Risperidone 5.1 mg pro die there was found 18.2% reduction on the Positive syndrome scale after two months. Negative syndrome scale showed improvement of 20.5%; General psychopathology scale was reduced for 15.7%. Finally, total PANSS score was reduced 17.2%. Results were also discussed according to sex, age, illness duration and schizophrenia type.ConclusionTherapeutically efficacy of Risperidone has been shown on the positive, as so as the negative schizophrenia symptoms. Better results were in disorganized form of schizophrenia then the paranoid form.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
